The outlook of companies tied to iconic drugs like Viagra presents a nuanced investment landscape . While the initial boom of copyright, fueled by Viagra's unprecedented popularity, generated substantial profits , the loss of exclusivity in key regions has introduced substantial volatility. Investors are now facing the impact of generic competition